BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating...
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively...
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary...
Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04,...
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003 – in HPV16-positive recurrent and/or...
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to...
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
Toronto, Ontario--(Newsfile Corp. - March 31, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") announces it...
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased...
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic...
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Achieved record revenue of $36.2 million, representing 21% increase over the year 2021 Company to host conference call and webcast...
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human...
Saint-Herblain (France), March 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the...
Nancy K. Bryan Nancy K. BryanOCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”...
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 -- -- The...
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancerFLORHAM...